Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population.

BACKGROUND We performed an epigenetic analysis of the first exon of the hVIM gene and the SFRP2 in circulating tumor cells (CTCs) and correlation with the corresponding primary colorectal cancer (CRC) tissue. PATIENTS AND METHODS CTCs detection in 52 colorectal cancer patients was managed by a multi-marker immunomagnetic method with the use of quantum dots (QDs). To determine methylation levels we used high-resolution melting (HRM) technology. RESULTS In the case of VIM we found 76.9% methylated samples, compared to 53.8% in tissue samples. Regarding SFRP2 promoter methylation levels in tissue and CTCs samples, 67.3% and 73.1%, were found methylated respectively. Correlation analysis of methylation levels with KRAS and BRAF mutations (performed in our previous study) demonstrates that high-methylation epigenotype strongly correlates to BRAF mutation. CONCLUSION CTCs is a promising diagnostic tool. The combination of genetic mutations and epigenetic aberrations specifically in CTCs, will ameliorate CRC diagnosis in the future.

[1]  Xinjun Zhang,et al.  Methylation of SFRP2 gene as a promising noninvasive biomarker using feces in colorectal cancer diagnosis: a systematic meta-analysis , 2016, Scientific Reports.

[2]  B. Broom,et al.  Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin , 2016, Oncotarget.

[3]  H. Brenner,et al.  Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review , 2016, Clinical Epigenetics.

[4]  E. Lianidou.  Gene expression profiling and DNA methylation analyses of CTCs , 2016, Molecular oncology.

[5]  M. Daidone,et al.  Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS‐BRAF wild‐type colorectal cancer receiving cetuximab or panitumumab , 2015, International journal of cancer.

[6]  M. Gazouli,et al.  Mutational Analysis of Circulating Tumor Cells from Colorectal Cancer Patients and Correlation with Primary Tumor Tissue , 2015, PloS one.

[7]  G. Barrière,et al.  Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. , 2014, Annals of translational medicine.

[8]  W. Xu,et al.  Negative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma. , 2014, World journal of gastroenterology.

[9]  M. Tzardi,et al.  KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer , 2014, PloS one.

[10]  Shiliang Huang,et al.  DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA , 2014, Oncology letters.

[11]  K. Hibi,et al.  Serum vimentin methylation as a potential marker for colorectal cancer. , 2014, Anticancer research.

[12]  A. Allan,et al.  Recent Advances in the Molecular Characterization of Circulating Tumor Cells , 2014, Cancers.

[13]  N. Cho,et al.  Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location , 2013, British Journal of Cancer.

[14]  M. Gazouli,et al.  Development of a quantum-dot-labelled magnetic immunoassay method for circulating colorectal cancer cell detection. , 2012, World journal of gastroenterology.

[15]  Rafael López-López,et al.  Molecular Characterization of Circulating Tumor Cells in Human Metastatic Colorectal Cancer , 2012, PloS one.

[16]  D. Ahlquist,et al.  Stool DNA testing for the detection of pancreatic cancer , 2012, Cancer.

[17]  Jun Liu,et al.  Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. , 2011, Clinical and investigative medicine. Medecine clinique et experimentale.

[18]  H. Nemoto,et al.  Aberrant methylation of the Vimentin gene in hepatocellular carcinoma. , 2011, Anticancer research.

[19]  R. Ned,et al.  Fecal DNA testing for Colorectal Cancer Screening: the ColoSure™ test , 2011, PLoS currents.

[20]  R. Palmqvist,et al.  The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status , 2010, Clinical Cancer Research.

[21]  H. Nemoto,et al.  Frequent methylation of Vimentin in well-differentiated gastric carcinoma. , 2009, Anticancer research.

[22]  Jun Liang,et al.  DNA hypermethylation of the vimentin gene inversely correlates with vimentin expression in intestinal- and diffuse-type gastric cancer. , 2016, Oncology letters.

[23]  Jacob C. Ulirsch,et al.  Vimentin DNA methylation predicts survival in breast cancer , 2012, Breast Cancer Research and Treatment.

[24]  P. Laird,et al.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer. , 2012, Genome research.